Jul 01, 2025
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
Jun 27, 2025
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
Apr 01, 2025
Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
Feb 05, 2025
Sobi publishes Q4 2024 report: A solid ending to a strong year
Dec 11, 2024
Bulletin from Sobi's Extraordinary General Meeting (EGM)
Oct 24, 2024
Sobi Q3 2024 report: Strong growth and significant pipeline momentum
Aug 29, 2024
Sobi has completed issues of class C shares
Jul 15, 2024
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
Jun 19, 2024
European Commission grants Sobi® Marketing Authorisation for ALTUVOCT(TM) for treatment of haemophilia A
May 14, 2024
Bulletin from Sobi's Annual General Meeting (AGM)
Apr 25, 2024
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Feb 08, 2024
Sobi publishes Q4 2023 report: Strong revenue performance and growth into 2024
Feb 18, 2021
Sobi publishes report for the fourth quarter and full-year 2020
Feb 16, 2021
Kineret® (anakinra) approved in Russia for the treatment of CAPS
Feb 03, 2021
Invitation - Presentation of Sobi's Q4 and FY 2020 results
Jan 20, 2021
Doptelet® (avatrombopag) approved in the EU for treatment of ITP
Dec 11, 2020
Doptelet® (avatrombopag) receives positive opinion from CHMP for treatment of ITP
Dec 10, 2020
Sobi and Apellis report positive top-line results at 48 weeks from the phase 3 PEGASUS study of pegcetacoplan in PNH
Dec 10, 2020
Emapalumab submission in China for primary HLH
Dec 07, 2020
Agenda: Sobi Capital Markets Day 2020